Abstract
Doxorubicin is believed to cause dose-dependent cardiotoxicity through redox cycling and the generation of reactive oxygen species (ROS). Here we show that cardiomyocyte-specific deletion of Top2b (encoding topoisomerase-IIβ) protects cardiomyocytes from doxorubicin-induced DNA double-strand breaks and transcriptome changes that are responsible for defective mitochondrial biogenesis and ROS formation. Furthermore, cardiomyocyte-specific deletion of Top2b protects mice from the development of doxorubicin-induced progressive heart failure, suggesting that doxorubicin-induced cardiotoxicity is mediated by topoisomerase-IIβ in cardiomyocytes.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy – a prospective analysis
Cardio-Oncology Open Access 27 April 2023
-
Anthracycline cardiotoxicity: current methods of diagnosis and possible role of 18F-FDG PET/CT as a new biomarker
Cardio-Oncology Open Access 27 March 2023
-
Recent Advances in Serum Biomarkers for Risk Stratification and Patient Management in Cardio-Oncology
Current Cardiology Reports Open Access 15 February 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
194,30 € per year
only 16,19 € per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout


Accession codes
References
Yeh, E.T. & Bickford, C.L. J. Am. Coll. Cardiol. 53, 2231–2247 (2009).
Force, T. & Kolaja, K.L. Nat. Rev. Drug Discov. 10, 111–126 (2011).
Tewey, K.M., Rowe, T.C., Yang, L., Halligan, B.D. & Liu, L.F. Science 226, 466–468 (1984).
Capranico, G., Tinelli, S., Austin, C.A., Fisher, M.L. & Zunino, F. Biochim. Biophys. Acta 1132, 43–48 (1992).
Lyu, Y.L. et al. Mol. Cell. Biol. 26, 7929–7941 (2006).
Singal, P.K. & Iliskovic, N. N. Engl. J. Med. 339, 900–905 (1998).
Myers, C. et al. Semin. Oncol. 10, 53–55 (1983).
Martin, E. et al. Toxicology 255, 72–79 (2009).
Lyu, Y.L. et al. Cancer Res. 67, 8839–8846 (2007).
Lyu, Y.L. & Wang, J.C. Proc. Natl. Acad. Sci. USA 100, 7123–7128 (2003).
Sohal, D.S. et al. Circ. Res. 89, 20–25 (2001).
Okamura, S. et al. Mol. Cell 8, 85–94 (2001).
Ogasawara, J. et al. Nature 364, 806–809 (1993).
Plesca, D., Mazumder, S. & Almasan, A. Methods Enzymol. 446, 107–122 (2008).
Arany, Z. et al. Proc. Natl. Acad. Sci. USA 103, 10086–10091 (2006).
Lai, L. et al. Genes Dev. 22, 1948–1961 (2008).
Wang, J. et al. Circ. Res. 106, 1904–1911 (2010).
Wallace, K.B. Pharmacol. Toxicol. 93, 105–115 (2003).
Sahin, E. et al. Nature 470, 359–365 (2011).
Ju, B.G. et al. Science 312, 1798–1802 (2006).
Liao, R. & Jain, M. Methods Mol. Med. 139, 251–262 (2007).
Bawa-Khalfe, T., Cheng, J., Wang, Z. & Yeh, E.T. J. Biol. Chem. 282, 37341–37349 (2007).
Ishii, K.A. et al. Nat. Med. 15, 259–266 (2009).
Zeisberg, E.M. et al. Nat. Med. 13, 952–961 (2007).
Acknowledgements
We thank C.H. Ren for expert technical assistance and F.M. Lin and H. Dou for conducting studies on mitochondria DNA. W.C. Claycomb (Louisiana State University Health Science Center) provided HL-1 cells. This study is supported by the Cancer Prevention Research Institute of Texas and McNair Medical Institute (E.T.H.Y.), US National Institutes of Health grant CA102463 (to L.F.L.), the New Jersey Commission on Cancer Research Grant 06-2419-CCR-EO, US Department of Defense Idea Award W81XWH-07-1-0407 and Concept Award W81XWH06-1-0514 (to Y.L.L.).
Author information
Authors and Affiliations
Contributions
E.T.H.Y. and L.F.L. conceived the project. S.Z., X.L., T.B.-K., L.-S.L. and Y.L.L. performed experiments and data analysis. E.T.H.Y. and S.Z. wrote the manuscript with editorial input from L.F.L. and Y.L.L.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–5 and Supplementary Tables 1 and 2 (PDF 896 kb)
Rights and permissions
About this article
Cite this article
Zhang, S., Liu, X., Bawa-Khalfe, T. et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 18, 1639–1642 (2012). https://doi.org/10.1038/nm.2919
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.2919
This article is cited by
-
Anthracycline cardiotoxicity: current methods of diagnosis and possible role of 18F-FDG PET/CT as a new biomarker
Cardio-Oncology (2023)
-
Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy – a prospective analysis
Cardio-Oncology (2023)
-
ATM inhibitor KU60019 synergistically sensitizes lung cancer cells to topoisomerase II poisons by multiple mechanisms
Scientific Reports (2023)
-
Epirubicin Treatment Induces Neurobehavioral, Oxido-Inflammatory and Neurohistology Alterations in Rats: Protective Effect of the Endogenous Metabolite of Tryptophan − 3-Indolepropionic Acid
Neurochemical Research (2023)
-
Recent Advances in Serum Biomarkers for Risk Stratification and Patient Management in Cardio-Oncology
Current Cardiology Reports (2023)